Congenital mesoblastic nephroma: a study of 19 cases using immunohistochemistry and ETV6-NTRK3 fusion gene rearrangement-Reference-Cited by-同舟云学术

Congenital mesoblastic nephroma: a study of 19 cases using immunohistochemistry and ETV6-NTRK3 fusion gene rearrangement

Published:2016-01 Issue:1 Volume:48 Page:47-50
ISSN:0031-3025
Container-title:Pathology
language:en
Short-container-title:Pathology

Author:

El Demellawy Dina,Cundiff Caitlin A.,Nasr Ahmed,Ozolek John A.,Elawabdeh Nancy,Caltharp Shelley A.,Masoudian Pourya,Sullivan Katrina J.,de Nanassy Joseph,Shehata Bahig M.

Publisher

Elsevier BV

Subject

Pathology and Forensic Medicine

Reference18 articles.

1. Ultrastructure of cellular congenital mesoblastic nephroma;O'Malley;Ultrastruct Pathol,1996

2. A comprehensive analysis of PAX8 expression in human epithelial tumors;Laury;Am J Surg Pathol,2011

3. Prenatal diagnosis of congenital mesoblastic nephroma in 2 siblings;Fuchs;J Ultrasound Med,2003

4. Mesoblastic nephroma—a report from the Gesellschaft fur Pädiatrische Onkologie und Hämatologie (GPOH);Furtwaengler;Cancer,2006

5. ETV6-NTRK3 gene fusions and trisomy 11 establish a histogenetic link between mesoblastic nephroma and congenital fibrosarcoma;Knezevich;Cancer Res,1998

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Selective type II TRK inhibitors overcome xDFG mutation mediated acquired resistance to the second-generation inhibitors selitrectinib and repotrectinib;Acta Pharmaceutica Sinica B;2024-02

2. Imaging characterization of paediatric tumours with the neurotrophic tyrosine receptor kinase fusion transcript;British Journal of Radiology;2024-01-16

3. Safety of current treatment options for NTRK fusion-positive cancers;Expert Opinion on Drug Safety;2023-10-31

4. Phase separation underlies signaling activation of oncogenic NTRK fusions;Proceedings of the National Academy of Sciences;2023-10-09

5. Survival Outcomes of Patients With Tropomyosin Receptor Kinase Fusion-Positive Cancer Receiving Larotrectinib Versus Standard of Care: A Matching-Adjusted Indirect Comparison Using Real-World Data;JCO Precision Oncology;2023-01